A Multi-center, Open, Single-arm Phase IIb Clinical Study to Evaluate the Safety and Efficacy of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
Latest Information Update: 26 May 2025
At a glance
- Drugs MT 1013 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Shaanxi Micot Technology Co
Most Recent Events
- 26 May 2025 New trial record